日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

Chinese researchers: HCQ ineffective in treating COVID-19

By ZHOU WENTING in Shanghai | chinadaily.com.cn | Updated: 2020-05-18 19:48
Share
Share - WeChat

The latest clinical trial by Chinese researchers has found that hydroxychloroquine (HCQ) is not effective in treating patients who are mildly and moderately ill with COVID-19, experts announced at a news briefing on Monday.

The paper about the study was published on the website of the British Medical Journal on May 15. It the world's first multi-center study of its kind to be released on a medical journal.

The randomized controlled clinical trial was conducted at 16 Chinese hospitals designated as COVID-19 treatment centers.

HCQ, an antimalaria and anti-inflammatory drug, has been used in several countries to treat COVID-19 and was recommended by the United States government as a viable treatment option.

"Compared with standard treatments, the use of HCQ for COVID-19 patients did not provide extra benefits, and there exists a higher incidence rate of adverse drug reactions," said Xie Qing, director of the infectious disease department at Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, which led the multi-center research.

She said that the result of the trial did not support the use of the drug, which was previously proven to be effective in inhibiting the novel coronavirus through in vitro tests. It was subsequently approved for use on mildly and moderately ill patients by several countries, including France and the US.

The trial involved 150 patients who were randomly split into two groups. Half of the patients were treated according to the national treatment guidelines while the other half were given 1,200 milligrams of the drug for the first three days and 800 mg for the remaining days.

After 28 days of treatment, the rate of the virus turning negative was 85.4 percent for the first group and 81.3 percent for the one that received HCQ.

Researchers also pointed out that the rate of adverse drug reactions among the group given HCQ was 30 percent, higher than the other group which had just 9 percent. The adverse reactions were mainly diarrhea and vomiting.

Qu Jieming, Party secretary of Ruijin Hospital, said that the participants were included in the study after showing symptoms for a median of 16.6 days. He added that the research findings have provided an insight into the potential conduct of studies in the future to determine if the drug would be effective if used earlier on patients.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 精品欧美一区二区三区久久久 | 91av一区| 亚洲免费精品 | 69久久国产精品热88人妻 | WWW国产亚洲精品久久久 | 亚洲综合一二三区 | 国产欧美性综合视频性刺激 | 国产一区二区自拍 | 色综合久久精品中文字幕首页 | 黄色毛片a| 中文字幕日本亚洲欧美不卡 | 桥本有菜免费av一区二区三区 | 国产欧美日韩一区二区三区四区 | 国产精品久久久久久喷浆 | 午夜爽爽性刺激一区二区视频 | 欧美ab在线 | 欧美一区二区三区在线观看免费 | 天天色综合社区 | 欧美一区二区视频 | 亚洲精品久久久 | 日韩在线不卡 | 欧美福利| 色网站视频 | 欧美一级爆毛片 | 亚洲精品久久视频 | 免费视频97碰碰碰在线观看 | 91www在线观看| 国产精品久久久久影视青草 | 激情五月六月婷婷 | 久久精品探花 | 超97在线观看精品国产 | 日本女人毛茸茸 | 日韩成人免费观看 | 免费视频片在线观看大片 | 欧美日韩一区二区在线视频播放 | 婷婷成人亚洲 | 排球少年第四季樱花动漫 | 欧美一级黄色网 | 久在线| 亚洲精品综合一区二区三 | 久草在线播放视频 |